US OptionsDetailed Quotes
MESO241220P8000
- 0.30
- +0.05+20.00%
15min DelayClose Nov 29 13:00 ET
0.30High0.30Low
0.30Open0.25Pre Close11 Volume65 Open Interest8.00Strike Price330.00Turnover169.27%IV34.13%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry0.30Extrinsic Value100Contract SizeAmericanOptions Type-0.1248Delta0.0438Gamma33.40Leverage Ratio-0.0233Theta-0.0009Rho-4.17Eff Leverage0.0057Vega
Mesoblast Stock Discussion
Sign in to post a comment
$Mesoblast (MESO.US)$ …got approval from FDA??
1
$Mesoblast (MESO.US)$ How low will it go?
1
1
$Mesoblast (MESO.US)$ … today back to 10
1
7
$Mesoblast (MESO.US)$ .. will drop then rocket by end of this year
1
2
$Mesoblast (MESO.US)$
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch | MESO Stock News
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch | MESO Stock News
1
1
$Mesoblast (MESO.US)$ .. if below to 5.. nice to buy!!!
2
4
$Mesoblast (MESO.US)$ Mesoblast (MESO) has released an update. Mesoblast Limited has resubmitted a Biologics License Application (BLA) to the FDA for Ryoncil®, aiming to treat children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD). The resubmission, buoyed by promising Phase 3 study results demonstrating significant survival benefits, could meet an urgent need for effective treatment in this patient group, as current survival outcomes are poor and no FDA-approved treatm...
2
8
$Mesoblast (MESO.US)$ which is developing off-the-shelf cellular medicines for life-threatening inflammatory conditions, is planning to file a Biologics License Application for Ryoncil with the FDA next week.
2
2
No comment yet
Aariya : may be almost there or already done but not yet published